ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0766

Understanding Patient Receptivity Towards Receipt of Prognostic Risk Score for Diabetic Kidney Disease

Session Information

Category: Diabetic Kidney Disease

  • 602 Diabetic Kidney Disease: Clinical

Authors

  • Muller, Tamara Sonetta, Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • Naik, Nidhi, Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • Rathi, Shivani, Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • Martin, Sharlene, Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • Zabetian, Azadeh, Icahn School of Medicine at Mount Sinai, New York, New York, United States
Background

Few studies examined the attitudes of patients with diabetic kidney disease (DKD) on risk stratification tools. An intrinsic barrier to undertake a risk stratification test is knowledge, awareness, and desire to know the risk of kidney disease. This study aimed at exploring the baseline knowledge about kidney disease and type 2 diabetes mellitus (T2DM) as a major contributing factor, alongside possible motivators, and the patient’s receptivity towards risk score delivery of KidneyIntelX, a novel prognostic test that assesses the risk of kidney disease progression over the next 5 years in patients with DKD stages 1-3.

Methods

In May 2021, we contacted a subset of patients with stages 1-3 DKD and T2DM at one primary care site at the Mount Sinai Health System to communicate results obtained on their KidneyIntelX test and we administered a survey. We assessed patient knowledge about the test, their receptivity, and attitude on the usefulness of the test to improve their kidney health.

Results

A subset of patients (n=37) tested with KidneyIntelX in May 2021 were successfully contacted by the APRN on the DKD Care Navigation Team at Mount Sinai and completed the post-test survey. The majority of patients (70%) were aware diabetes is a contributing factor to kidney disease. 73% were unfamiliar with the prognostic test goals, while 27% were provided with an explanation by their physician. 89% were appreciative of the post-test call, and receiving risk scores through a post-test call were helpful for all patients (60% helpful, 40% very helpful) in improving their understanding of kidney health. Additionally, all patients were motivated to implement lifestyle changes to improve kidney health, and 63% desired educational content on diabetes, kidney disease and diet (Table).

Conclusion

Dedicated phone calls from the Care Navigation Team after KidneyIntelX testing enhanced patient understanding about kidney disease and revealed substantial motivation to take appropriate actions and receive further education for their kidney health.

Funding

  • Commercial Support